Nykode Therapeutics ASVACBF -1.05%28 Altman Z2-Score is 15.84 as of Jun. 28, 2026, which is 67% above its 10-year median of 9.50. GuruFocus rates VACBF with a GF Score™ of 28/100 and a GF Value™ of $0.64 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Nykode Therapeutics AS ranks better than 90.33% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Nykode Therapeutics AS has a Altman Z2-Score of 15.84, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Nykode Therapeutics AS's Altman Z2-Score or its related term are showing as below:
VACBF'
s Altman Z2-Score Range Over the Past 10 Years
Min: 6.38 Med: 9.5 Max: 18.55
Current: 15.8
During the past 9 years, Nykode Therapeutics AS's highest Altman Z2-Score was 18.55. The lowest was 6.38. And the median was 9.50.
Nykode Therapeutics AS (OTCPK:VACBF) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Nykode Therapeutics AS Altman Z2-Score Related Terms
Nykode Therapeutics AS Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Nykode Therapeutics AS's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VACBF vs VRTX, REGN, ALNY: Altman Z2-Score Comparison
For the Biotechnology subindustry, Nykode Therapeutics AS's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's Altman Z2-Score falls into.
Nykode Therapeutics AS Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Nykode Therapeutics AS (VACBF) has a Altman Z2-Score of 15.84 as of Jun. 28, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Nykode Therapeutics AS and its competitors. This is 67% above median its historical median of 9.50. Over the past decade, Nykode Therapeutics AS's Altman Z2-Score has ranged from 6.38 to 18.55. According to the industry distribution chart, Nykode Therapeutics AS ranks #135 out of 1396 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Nykode Therapeutics AS's Altman Z2-Score too high?
Nykode Therapeutics AS's current Altman Z2-Score of 15.84 is 67% above median its 10-year median of 9.50. Over the past 10 years, this metric has ranged from a low of 6.38 to a high of 18.55. Based on the distribution chart, Nykode Therapeutics AS ranks #135 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #135 out of 1396 companies for Altman Z2-Score. This places Nykode Therapeutics AS in the top 10% of its industry — outperforming the majority of peers. Historically, Nykode Therapeutics AS's own Altman Z2-Score has ranged from 6.38 to 18.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Altman Z2-Score is 15.84, which is 67% above median its own 10-year median of 9.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.32 — trading 49.8% below its estimated fair value. The current Altman Z2-Score is 15.84, which is 67% above median its 10-year median of 9.50. Nykode Therapeutics AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Altman Z2-Score is 15.84 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of $0.32 is trading 49.8% below its estimated GF Value™ of $0.64.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for VACBF:
Altman Z2-Score: 15.84 (67% above median its 10-year median of 9.50)
GF Value™: $0.64 vs. price of $0.32 (49.8% below fair value)
No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
28GF Score
Get the complete analysis for VACBF
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VACBF has been successfully added to your 
